FRTX-02

FRTX-02 is a potent, highly selective, and orally bioavailable small molecule inhibitor of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). It is being developed as a potential first-in-class therapy for autoimmune and inflammatory diseases. The drug aims to restore immune homeostasis by modulating both adaptive and innate immune responses. Mechanistically, FRTX-02 supports the function of anti-inflammatory regulatory T cells while inhibiting pro-inflammatory pathways—including MyD88/IRAK4-related signaling—resulting in reduced production of disease-relevant cytokines such as IFNγ, IL-23, IL-10, IL-6, and TNFα. Unlike broad immunosuppressants like JAK inhibitors or anti-TNF biologics that increase infection risk due to global immune suppression, FRTX-02 offers a more targeted approach by rebalancing immune cell populations and cytokine signaling. Preclinical studies have shown efficacy in models of atopic dermatitis and rheumatoid arthritis[3][4][5][6][9].